{"Symbol": "ANEB", "AssetType": "Common Stock", "Name": "Anebulo Pharmaceuticals Inc", "Description": "Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients suffering from cannabinoid overdose and addiction. The company is headquartered in Lakeway, Texas.", "CIK": "1815974", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "1017 RANCH ROAD 620 SOUTH, LAKEWAY, TX, UNITED STATES, 78734", "OfficialSite": "https://www.anebulo.com", "FiscalYearEnd": "June", "LatestQuarter": "2025-12-31", "MarketCapitalization": "19535900", "EBITDA": "None", "PERatio": "None", "PEGRatio": "None", "BookValue": "0.193", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-0.22", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.45", "ReturnOnEquityTTM": "-0.697", "RevenueTTM": "0", "GrossProfitTTM": "0", "DilutedEPSTTM": "-0.22", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "3", "AnalystRatingStrongBuy": "-", "AnalystRatingBuy": "-", "AnalystRatingHold": "-", "AnalystRatingSell": "-", "AnalystRatingStrongSell": "-", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "-", "PriceToBookRatio": "1.977", "EVToRevenue": "-", "EVToEBITDA": "-6.54", "Beta": "-0.812", "52WeekHigh": "3.42", "52WeekLow": "0.435", "50DayMovingAverage": "1.312", "200DayMovingAverage": "1.874", "SharesOutstanding": "40784700", "SharesFloat": "3376600", "PercentInsiders": "40.835", "PercentInstitutions": "54.761", "DividendDate": "None", "ExDividendDate": "None"}